Review



customised microarray mammaprint  (Agendia BV)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Agendia BV customised microarray mammaprint
    Customised Microarray Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/microarray+based+mammaprint/pm19955335-30-9-16
    Average 90 stars, based on 1 article reviews
    customised microarray mammaprint - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Modern Methods for Breast Cancer Diagnosis and Classification: A Current Update
    Article Snippet: The incidence of cancer-related deaths worldwide has increased by 66% since 1960, according to the International Agency for Research on Cancer (IARC).. A breast cancer diagnosis is predicted to occur in one in eight women in the US alone at some point in their lifetime.. A BC diagnosis is typically made using high-end molecular bioimaging, ultrasound, and mammography.

    Article Title: Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry.
    Article Snippet: Examples of these are the microarray-based clinical tests, such as MammaPrint (Agendia) [31] and ColoPrint (Agendia) [32] for breast and colon cancer recurrence risk prognosis, respectively, and the rising RNA seq-based tests, which are having significant prognostic and therapeutic relevance to cancer due to their capability of high reproducibility, accuracy, and precision [30,33,34].

    Article Title: Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles
    Article Snippet: Three multigene expression assays (PCR-based OncotypeDX (Genomic Health Inc., Redwood City, CA, USA) , , microarray-based MammaPrint (Agendia Inc., Amsterdam, Netherlands) , , NanoString-based PAM50 Prosigna Assay (NanoString Technologies Inc., Seattle, WA, USA) , ) have been used determine the risk of recurrence in patients with breast cancer.

    Article Title: Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry
    Article Snippet: Examples of these are the microarray-based clinical tests, such as MammaPrint (Agendia) [ ] and ColoPrint (Agendia) [ ] for breast and colon cancer recurrence risk prognosis, respectively, and the rising RNA seq-based tests, which are having significant prognostic and therapeutic relevance to cancer due to their capability of high reproducibility, accuracy, and precision [ , , ].

    Article Title: MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
    Article Snippet: To be eligible for enrollment, patients with HR+/HER2− breast cancer also need to be at high risk for recurrence based on the MammaPrint (Agendia, Irvine, CA, USA) genomic test.

    Article Title: Considering adjuvant therapy for stage II melanoma
    Article Snippet: GEP testing for patients with breast cancer (Oncotype [Genomic Health Inc], MammaPrint [Agendia Inc]) is already well established and validated as an essential component to women with early stage breast cancer and defines treatment strategies, including the decision whether to offer adjuvant chemotherapy.

    Microarray:

    Article Title: Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ : evidence supporting the use of diverse pathways panels
    Article Snippet: .. Available predictive tests include the Agendia Mammoprint (microarray), Breast Cancer Index (qRT-PCR), EndoPredict (qRT-PCR), Oncotype DX (qRT-PCR), and Prosigna (NanoString technology) assays [ 1 – 5 ]. ..

    Gene Expression:

    Article Title: Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling
    Article Snippet: .. In this scenario, personalized prediction tools such as gene expression profiling (eg, OncotypeDX [Genomic Health Inc., Redwood City, CA] or Mammaprint [Agendia Inc., Amsterdam, the Netherlands]) can calculate the likelihood of cancer recurrence and can help to risk stratify women who may not benefit from chemotherapy, sparing them from associated toxicity. ..



    Similar Products

    customised oligonucleotide microarray  (Agilent technologies)
    90
    Agilent technologies customised oligonucleotide microarray
    Customised Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/pm25195018-60-10-12
    Average 90 stars, based on 1 article reviews
    customised oligonucleotide microarray - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    customised microarray  (Thermo Fisher)
    90
    Thermo Fisher customised microarray
    Customised Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/pm38760882-1878-157-129
    Average 90 stars, based on 1 article reviews
    customised microarray - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    genotyping microarray customised for the eurogenomics cooperative  (Illumina Inc)
    90
    Illumina Inc genotyping microarray customised for the eurogenomics cooperative
    Genotyping Microarray Customised For The Eurogenomics Cooperative, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/genotyping+microarray+customised+for+the+eurogenomics+cooperative/bio_rxiv__2024__03__23__586433-38-9-3
    Average 90 stars, based on 1 article reviews
    genotyping microarray customised for the eurogenomics cooperative - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pepperchip® customised peptide microarrays  (PEPperPRINT gmbh)
    90
    PEPperPRINT gmbh pepperchip® customised peptide microarrays
    Pepperchip® Customised Peptide Microarrays, supplied by PEPperPRINT gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/pepperchip+peptide+microarrays/pmc07001291-250-19-33
    Average 90 stars, based on 1 article reviews
    pepperchip® customised peptide microarrays - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    horse gene expression microarray with 43,803 probes that can be customised to meet specific research needs  (Agilent technologies)
    90
    Agilent technologies horse gene expression microarray with 43,803 probes that can be customised to meet specific research needs
    Horse Gene Expression Microarray With 43,803 Probes That Can Be Customised To Meet Specific Research Needs, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/pmc04327934-167-4-1
    Average 90 stars, based on 1 article reviews
    horse gene expression microarray with 43,803 probes that can be customised to meet specific research needs - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    customised murine microarrays  (Ocimum Biosolutions)
    90
    Ocimum Biosolutions customised murine microarrays
    Customised Murine Microarrays, supplied by Ocimum Biosolutions, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/customised+murine+microarrays/pm22155623-92-1-4
    Average 90 stars, based on 1 article reviews
    customised murine microarrays - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    customised microarray mammaprint  (Agendia BV)
    90
    Agendia BV customised microarray mammaprint
    Customised Microarray Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/microarray+based+mammaprint/pm19955335-30-9-16
    Average 90 stars, based on 1 article reviews
    customised microarray mammaprint - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    customised gene chips for dna microarray analysis  (Ocimum Biosolutions)
    90
    Ocimum Biosolutions customised gene chips for dna microarray analysis
    Customised Gene Chips For Dna Microarray Analysis, supplied by Ocimum Biosolutions, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/customised+gene+chips+for+dna+microarray+analysis/pmc03031898-68-1-10
    Average 90 stars, based on 1 article reviews
    customised gene chips for dna microarray analysis - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    customised 11 kb oligonucleotide-microarray  (Agilent technologies)
    90
    Agilent technologies customised 11 kb oligonucleotide-microarray
    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to <t>microarray</t> analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.
    Customised 11 Kb Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/customised+microarray/pmc02768442-36-29-31
    Average 90 stars, based on 1 article reviews
    customised 11 kb oligonucleotide-microarray - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-4 and friend-of-GATA ( FOG )-2 according to microarray analyses. ( A – D ) GATA-4 and ( E – H ) FOG-2 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =32 for GATA-4 ; n =33 for FOG-2 ). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Boxes: median expression values (horizontal line) and twenty-fifth and seventy-fifth percentiles; whiskers: distances from the end of the box to the largest and smallest observed values that are <1.5 box lengths from either end of the box; open circles: outlying values; asterisks: extreme values. ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY

    Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Journal: British Journal of Cancer

    Article Title: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

    doi: 10.1038/sj.bjc.6605276

    Figure Lengend Snippet: Relative expression levels of GATA-2 and -3 according to microarray analyses. ( A – D ) GATA-2 and ( E – H ) GATA-3 . ( A and E ) MYCN -nonamplified ( n =218) vs MYCN -amplified ( n =33). ( B and F ) Localised stages ( n =153) vs stage 4 ( n =67) vs stage 4S ( n =31). ( C and G ) Patients below 1 year ( n =94) vs above 1 year ( n =157). ( D and H ) High-risk (HR; n =82) vs low-risk (LR; n =169) tumours according to the PAM classification. Expression values are given in log ratios (sample vs reference RNA). Box plots represent data as in . * P <0.05; ** P <0.01; *** P <0.001 according to the nonparametric Mann–Whitney test.

    Article Snippet: In brief, 1 μ g of linearly amplified Cy3- and Cy5-labelled cRNA was hybridised together with 1 μ g of reverse colour Cy-labelled reference cRNA to a customised 11 kb oligonucleotide-microarray (Agilent Technologies, Waldbronn, Germany).

    Techniques: Expressing, Microarray, Amplification, MANN-WHITNEY